Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Castration Resistant Prostate Cancer (mCRPC) × Pluvicto × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 14 Metastatic Castration-resistant Prostate Cancer 2 Kidney Neoplasms 2 Carcinoma, Renal Cell 2 Renal Insufficiency 1 Prostatic Neoplasms, Castration-Resistant 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1

Interventions

Pluvicto 1 Lutetium-177 1 Lutetium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06894511 2026-02-17

PSMAndARPI

Novartis

Phase 2 Active not recruiting

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡